Rosiglitazone and Insulin Resistance in Renally Impaired Patients

Summary

30 non-diabetic, non-obese patients with stage 4 chronic kidney disease will be asked to participate in this metabolic study. The primary aim of this study is to determine the effect of rosiglitazone on insulin resistance in non-obese patients with non-diabetic stage 4 CKD. Secondary end points are the effects on inflammation (hsCRP), lipid profile, bone density and body composition.

Timeline

Start

2007-04

Primary completion

2008-03

Completion

2008-05

Drugs

Indications